Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Head and Neck Squamous Cell Carcinoma (HNSCC) : Update Bulletin [December 2016]

Product Code:
596200546
Publication Date:
December 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in the head and neck squamous cell carcinoma (HNSCC) market: the accelerated FDA approval of Keytruda (pembrolizumab; Merck & Co.) for the treatment of recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy; the approval of Opdivo (nivolumab; Bristol-Myers Squibb) by the FDA for the treatment of recurrent or metastatic HNSCC with disease progression on or after platinum-based chemotherapy; the implementation and subsequent lifting of the FDA partial hold on clinical trials of durvalumab (AstraZeneca), due to bleeding incidents.

Highlights from this event update bulletin

  • How do KOLs view the FDA approval of Merck & Co.’s Keytruda for the second-line treatment of recurrent or metastatic HNSCC?
  • How widely will Keytruda be used and will there be any barriers to its use in its newly approved indication?
  • How do KOLs react to the FDA approval of BMS’ Opdivo for the second-line treatment of recurrent or metastatic HNSCC, and will there be any barriers to its widespread use?
  • How do KOLs view the comparative efficacy and tolerability of Keytruda and Opdivo in the treatment of HNSCC?
  • How significant will the advantage for Keytruda be as the first PD-1/PD-L1 inhibitor to gain approval for HNSCC?
  • How will oncologists choose between Keytruda and Opdivo for the treatment of recurrent or metastatic HNSCC?
  • Will the temporary suspension of the Phase III development of AstraZeneca’s durvalumab impact its chance of success?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved